Affiliation:
1. SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania
Abstract
ABSTRACT
Two models of respiratory tract infection were used to investigate the pharmacodynamics of amoxicillin-clavulanate against
Streptococcus pneumoniae
. Eight strains of
S. pneumoniae
were used in a mouse model in which the animals were infected intranasally and were then treated with a range of doses and dose intervals. The time that the plasma amoxicillin concentration remained above the MIC (
T
>MIC) correlated well with bacterial killing, such that if
T
>MIC was below 20% there was no effect on bacterial numbers in the lungs. As
T
>MIC increased, the response, in terms of decreased bacterial load, improved and at
T
>MICs of greater than 35 to 40% of the dosing interval, bacteriological cure was maximal. On the basis of equivalent
T
>MICs, these data would suggest that in humans a dosage of 500 mg three times daily (t.i.d.) should have efficacy equal to that of a dosage of 875 mg twice daily (b.i.d.). This hypothesis was evaluated in a rat model in which amoxicillin-clavulanate was given by computer-controlled intravenous infusion to achieve concentrations that approximate the concentrations achieved in the plasma of humans following oral administration of 500/125 mg t.i.d. or 875/125 mg b.i.d. Infusions continued for 3 days and bacterial numbers in the lungs 2 h after the cessation of the infusion were significantly reduced (
P
< 0.01) by both treatments in strains of
S. pneumoniae
for which amoxicillin MICs were below 2 μg/ml. When tested against a strain of
S. pneumoniae
for which the amoxicillin MIC was 4 μg/ml, the simulated 500/125-mg dose was ineffective but the 875/125-mg dose demonstrated a small but significant (
P
< 0.01) reduction in bacterial numbers. These data confirm the findings in the mouse and indicate that amoxicillin-clavulanate administered at 875/125 mg b.i.d. would be as effective clinically as amoxicillin-clavulanate administered at 500/125 mg t.i.d.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference18 articles.
1. Andes
D.
Urban
A.
Craig
W. A.
In-vivo activity of amoxicillin and amoxicillin-clavulanate against penicillin-resistant pneumococci abstr. A82
Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy.
1995
16
American Society for Microbiology
Washington D.C
2. Antimicrobial resistance in Streptococcus pneumoniae: an overview.;Applebaum P. C.;Clin. Infect. Dis.,1992
3. Infections due to penicillin-resistant pneumococci. Clinical, epidemiologic, and microbiologic features.;Caputo G. M.;Arch. Intern. Med.,1993
4. Bacteriology of acute otitis media in adults.;Celin S. E.;JAMA,1991
5. Craig W. A. 1993. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur. J. Clin. Microbiol. Infect. Dis. 12 (Suppl. 1):6–8.
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献